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Dystonia is a debilitating hyperkinetic movement disorder, which can be transmitted as a monogenic trait. Here, we
describe homozygous frameshift, nonsense and missense variants in TSPOAP1, encoding the active zone RIM-binding
protein 1 (RIMBP1), as a novel genetic cause of autosomal recessive dystonia in seven subjects from three unrelated
families. Subjects carrying loss-of-function variants presented with juvenile-onset progressive generalized dystonia,
associated with intellectual disability and cerebellar atrophy. Conversely, subjects carrying a pathogenic missense variant
(p.Gly1808Ser) presented with isolated adult-onset focal dystonia. In mice, complete loss of RIMBP1, known to reduce
neurotransmission, led to motor abnormalities reminiscent of dystonia, decreased Purkinje cell dendritic arborization, and
reduced numbers of cerebellar synapses. In vitro analysis of the p.Gly1808Ser variant showed larger spike-evoked
calcium transients and enhanced neurotransmission, suggesting that RIMBP1-linked dystonia can be caused by either
reduced or enhanced rates of spike-evoked release in relevant neural networks. Our findings establish a direct link
between dysfunction of the presynaptic active zone and dystonia and highlight the critical role played by well-balanced
neurotransmission in motor control and disease pathogenesis.
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ABSTRACT 
Dystonia is a debilitating hyperkinetic movement disorder, which can be transmitted as 
a monogenic trait. Here, we describe homozygous frameshift, nonsense and missense 
variants in TSPOAP1, encoding the active zone RIM-binding protein 1 (RIMBP1), as a 
genetic cause of autosomal recessive dystonia in seven subjects from three unrelated 
families. Subjects carrying loss-of-function variants presented with juvenile-onset 
progressive generalized dystonia, associated with intellectual disability and cerebellar 
atrophy. Conversely, subjects carrying a pathogenic missense variant (p.Gly1808Ser) 
presented with isolated adult-onset focal dystonia. In mice, complete loss of RIMBP1, 
known to reduce neurotransmission, led to motor abnormalities reminiscent of 
dystonia, decreased Purkinje cell dendritic arborization, and reduced numbers of 
cerebellar synapses. In vitro analysis of the p.Gly1808Ser variant showed larger spike-
evoked calcium transients and enhanced neurotransmission, suggesting that RIMBP1-
linked dystonia can be caused by either reduced or enhanced rates of spike-evoked 
release in relevant neural networks. Our findings establish a direct link between 
dysfunction of the presynaptic active zone and dystonia and highlight the critical role 




Dystonia is a disabling hyperkinetic movement disorder characterized by an excess of 
sustained, often repetitive, involuntary twisting movements, and postures (1). 
Dystonia, after Parkinson’s disease and essential tremor, is the third most common 
movement disorder and has an estimated frequency of 732 per 100,000 in the general 
population (2). Clinically, dystonia can occur as an isolated symptom or in combination 
with other movement disorders or neurological abnormalities (3). 
 
Dystonia is thought to be a disorder of brain circuits involved in motor control (4, 5),  
with several lines of evidence locating its origin in the basal ganglia(6) or in the 
cerebellar connections (7). The precise cellular and molecular events responsible for 
the genesis of dystonic movements are not understood, hindering the development of 
more effective treatments. Importantly, pathogenic variants in a growing number of 
genes have been causally linked to dominant and recessive Mendelian forms of 
dystonia (8), allowing the development of genetic animal models and the initial 
delineation of converging molecular pathways in disease mechanisms (9). Along these 
lines, disruption of synaptic function has been recognized as a fundamental event in 
the pathogenesis of dystonia (10). 
 
Synaptic function relies on fast and precise spike-triggered neurotransmitter release at 
the presynaptic active zone (11). The active zone is a cytomatrix composed of several 
large protein families, including Munc13s, RIMs, ELKs, α-liprins, and RIM-binding 
proteins (12). These proteins contain multiple protein-protein interaction domains, 
which facilitates the formation of a densely interconnected protein network that enables 
docking and priming of synaptic vesicles for exocytosis and ensures rapid and efficient 
coupling between presynaptic calcium (Ca2+) influx and synaptic vesicle fusion (13).  
 
RIM-binding proteins (RIMBPs) are central components of the active zone that, in 
conjunction with RIMs, determine the precise localization of presynaptic voltage-gated 
Ca2+ channels (VGCCs) and ensure tight coupling between presynaptic action 
potentials and synaptic vesicle exocytosis (14, 15). RIMBPs comprise two main brain 
isoforms, RIMBP1 and RIMBP2, which are structurally similar and consist of a SH3 
domain at the N-terminal region, followed by three central fibronectin type-3 domains 
(FN3), and two additional SH3 domains in their most distal C-terminal regions (16). 
Mechanistically, it is via their SH3 domains that RIMBPs bind to the proline-rich 
sequences in the cytosolic domain of presynaptic VGCCs, tethering them to the active 
zone (14, 17), and controlling the precision and fidelity of neurotransmitter release and 
synaptic transmission (18, 19).  
 
Here, we demonstrate that rare homozygous truncating and missense variants in 
TSPOAP1 (MIM* 610764; previously known as BZRAP1), the gene encoding RIMBP1, 
cause autosomal recessive dystonia in three unrelated families. In mice, deletion of 
RIMBP1 caused motor abnormalities reminiscent of dystonia as well as changes in the 
biochemical composition and morphology of the cerebellum. Interestingly, the 
pathogenic missense variant rendered abnormally large presynaptic Ca2+ entry and 
increased transmitter release in response to presynaptic firing.  Altogether, our results 
highlight the critical role played by precisely fine-tuned synaptic transmission in normal 
motor function, and establish a direct link between RIMBP1-mediated neurotransmitter 
vesicle release and dystonia pathogenesis. 
Results  
 
Homozygous TSPOAP1/RIMBP1 variants cause autosomal recessive dystonia 
Using a combination of homozygosity mapping and whole-exome sequencing (WES), 
homozygous variants in TSPOAP1 were independently identified as the top candidate 
genetic cause of autosomal recessive dystonia in the three families reported herein 
(Figure 1; Suppl. Tables 1 and 2). The online platform GeneMatcher (20) was used to 
share results among the three groups that identified the variants.  
 
Family A is a consanguineous pedigree of Gujarati Indian origin (parents of the 
affected subjects are first cousins) (Figure 1A, left). Homozygosity mapping revealed 
a single candidate chromosomal region corresponding to a large run of homozygosity 
(ROH) of ~11,5 Mb on chromosome 17 (chr17:53,415,850–64,831,657), which was 
unique to the three affected family members. After applying the filtering strategy to 
WES data, only a single candidate causative variant remained, a frameshift deletion in 
TSPOAP1 (NM_004758.3:c.538delG, p.Ala180Profs*8) located within the disease-
associated ROH and shared by all three affected subjects. Sanger sequencing 
confirmed the presence of the variant and showed that both parents were 
heterozygous carriers while the healthy sibling was homozygous for the reference 
allele, thus confirming complete disease co-segregation. This frameshift variant is 
absent in more than 120,000 subjects listed in gnomAD, which contains >15,000 
subjects of South Asian ancestry.  
  
Family B is of Estonian origin and has been previously reported (21). There was no 
reported history of parental consanguinity. The proband is the only child in the family 
(Figure 1A, middle). Chromosomal microarray analysis did not detect CNVs. 
Homozygosity mapping revealed three large ROHs (chr4: 10,769,440 - 21,449,134; 
chr10:54,942,171-63,972,930; chr17:55,928,909-67,419,074) indicating likely 
unreported consanguinity. WES analysis identified a homozygous STOP-gain variant 
in TSPOAP1 (NM_004758.3:c.2449_2450delinsTG, p.Gln817*), located in the largest 
ROH as the best candidate. Sanger sequencing confirmed the presence of the 
homozygous variant in the proband and heterozygous in the mother (father’s DNA was 
not available). This variant is not present in gnomAD, which contains 2,418 Estonian 
subjects.  
  
Family C is of Turkish origin (Figure 1A, right). There was no reported consanguinity 
in the family but the parents came from the same village. Three large ROHs (chr8: 
33,406,218 - 42,407,799; chr11: 56,184,803 - 82,708,284; and chr17:54,967,949 - 
66,426,255) were found exclusively in the proband. WES analysis revealed three rare 
homozygous coding variants located within the identified ROHs, KCNU1 
(NM_001031836: c.1280T>C, p.Ile427Thr [rs570237282]), NADSYN1 
(NM_018161:c.278G>A, p.Arg93Gln [rs763061270]) and TSPOAP1 
(NM_004758.3:c.5422G>A, p.Gly1808Ser [rs752560074]). Amongst these, only the 
variant in TSPOAP1 was homozygous also in the other siblings affected by dystonia. 
The variant is predicted pathogenic by all in silico prediction tools and has a CADD 
score of 27.7. The variant is not present in the homozygous state in gnomAD (minor 
allele frequency 0.00001061) and is not present in the Great Middle East Variome 
database (22). Finally, the variant was absent in a further ~1000 Turkish families with 
unrelated medical conditions, thus excluding it as a common variant specific to the 
Turkish population.  
 
TSPOAP1 variants identified in families A and B are both predicted to render truncated 
RIMBP1 products lacking most if not all functional domains. Thus, the carriers of these 
variants represent essentially RIMBP1 knockout (KO) subjects (Figure 1D). In contrast, 
the p.Gly1808Ser variant found in Family C is a missense variant located in the last 
RIMBP1 SH3 domain, which is critical for its binding to VGCCs (14, 17), and shows 
complete evolutionary conservation across species down to invertebrates and in the 
human homolog RIMBP2 (Figure 1D).  
 
Loss-of-function variants are absent in ~ 15,000 in-house exomes sequenced at the 
three centers who analyzed the families and homozygous loss-of-function variants are 
not seen in a further ~130,000 subjects listed on gnomAD. Furthermore, we did not 
observe any homozygous rare TSPOAP1 missense variant located within any of the 
three functionally relevant SH3 domains in both in-house exomes and gnomAD, 
indicating that homozygous variants in these regions are exceedingly rare and adding 
further evidence in support of the pathogenic role of the variant identified in family C. 
Finally, mining WES data from an additional ~700 cases affected with different forms 
of dystonia, failed to identify additional cases with confirmed bi-allelic TSPOAP1 
changes. 
 
Clinical features of patients with bi-allelic TSPOAP1/RIMBP1 variants 
The clinical features of all subjects with TSPOAP1 variants are summarized in Table 
1. In brief, all four subjects with homozygous loss-of-function TSPOAP1 variants 
(Family A and B) shared a strikingly similar phenotype characterized by normal motor 
and language development, mild learning disabilities that first appeared in primary 
school, and onset in early teenage years of progressive generalized dystonia 
(Supplemental video 1). Dystonia displayed a clear craniocaudal gradient in all four 
subjects, with dystonic movements severely affecting the cranio-cervical district and to 
a lesser extent the trunk and the four limbs. The impairment of the cranial muscles was 
particularly severe, resulting in prominent dysphonia and dysarthria and progressive 
difficulties with swallowing. Upper limb examination showed continuous dystonic 
posturing, muscle overflow and writhing movements, resulting in impaired dexterity and 
severe handwriting difficulties. Gait examination showed progressive abnormalities 
including bilateral foot inward turning, tiptoeing, leg stiffening, and abnormal knee 
flexion, resulting in progressive loss of autonomous ambulation. 
 
All four cases showed clear evidence of cognitive deterioration. Formal cognitive 
assessment was performed in case A-II.1 (age 27; extensive cognitive impairment) 
and in subject B-II.1 (age 10 and 17; progression from mild to moderate intellectual 
disability). Other additional neurological features that were only variably observed 
included generalized tonic-clonic seizures (subject A-II.4; EEG showed bilateral 
interictal epileptic activity), superimposed episodes of limb and painful truncal dystonia 
triggered by sudden movements and controlled by treatment with phenytoin (subject 
A-II.2), and lower limb spasticity with hyperactive reflexes (subject B-II.1). 
 
Subjects from family C carrying the homozygous missense change p.Gly1808Ser 
presented with a milder dystonic phenotype, characterized by adult-onset focal 
dystonia or dystonic tremor (supplemental video 2). The index proband (C-II.4) 
developed dystonia at age 58 and on examination she had segmental dystonia 
affecting her neck and upper limbs. Two of the proband’s siblings presented in their 
60s with either isolated tremulous cervical dystonia and upper limb postural tremor 
(subject C-II.3) or isolated hand dystonic tremor (subject C-II.1). 
Patients with homozygous TSPOAP1/RIMBP1 loss-of-function variants display 
progressive cerebellar atrophy 
Brain MRI showed prominent cerebellar atrophy with a predominance for the vermis in 
all four subjects from Families A and B (Figure 1B), a finding that is highly atypical in 
cases with generalized dystonia. Serial brain imaging in subject A-IV.2 (MRI at age 5, 
8 and 14) and B-II.1 (MRI at age 15 and 17) documented progression of the cerebellar 
atrophy. The prominence of this radiological finding was in striking contrast with the 
paucity of classic clinical features of cerebellar dysfunction (i.e. ocular nystagmus, gait 
ataxia, limb dysmetria). Conversely, supratentorial, brainstem and spinal cord 
parenchyma had otherwise a normal appearance and there were no signal 
abnormalities or volume loss in the basal ganglia. Brain imaging was reported as 
normal in the proband of family C, but images were not available for direct review.  
 
Brain expression profile of TSPOAP1/RIMBP1 and its homolog RIMPB2 supports an 
essential role for RIMBP1 in cerebellar Purkinje neurons. (5, 7) (5, 7) (5, 7) (5, 7) 
Previous studies (16) as well as gene expression datasets from human and mouse 
brains, including GTEx (23) (human brain expression) and Brain Allen Atlas (mouse 
brain expression) (24), showed that both TSPOAP1 and its homolog RIMBP2 are 
highly expressed across several brain regions in a partly overlapping and partly 
segregated manner (Suppl. Figure 1). Importantly, in the cerebellum the expression of 
TSPOAP1/RIMBP1 was very high, particularly in Purkinje cells, while the expression 
of RIMBP2 was low throughout. A similar pattern of expression was observed in the 
striatum as well, though less pronounced than in the cerebellum. 
RIMBP1 and RIMBP2 are functionally redundant and can compensate for each other’s 
function when individually deleted (18, 19). The particular RIMBP expression pattern 
in Purkinje cells indicates that compensation might not occur in these cells, and thus 
suggests Purkinje cells might be particularly susceptible to RIMBP1 dysfunction 
caused by the identified TSPOAP1 pathogenic variants.  
 
Genetic deletion of RIMBP1, but not RIMBP2, triggers motor abnormalities in 
mice 
To support the pathogenic role of the identified homozygous loss-of-function RIMPB1 
variants, we pursued further studies in mice. For this, we generated RIMBP1-KO mice, 
as previously reported (25) (Supp. Figure 2A). RIMBP1-KO mice displayed normal 
weight and no obvious developmental abnormalities (Supp. Figure 2B), indicating that 
constitutive removal of RIMBP1 has no significant effects on mouse survival and gross 
development. 
We then tested whether RIMBP1-KO impacts mouse motor behaviors that are 
commonly disrupted in dystonia models. First, quantification of open field activity 
showed that KO mice displayed ~30% overall increase in spontaneous locomotor 
activity compared to WT littermates (Figure 2A). Second, in a beam-walk motor 
coordination test (Figure 2B), RIMBP1-KO mice showed nearly 100% more ‘slips’ and 
were significantly slower at crossing the beam than WT littermates (Supplemental 
video 3). Third, suspension of mice by their tail (Figure 2C and Supplemental video 4) 
for 10 or 20 seconds led to limb-clasping behavior in 80% of RIMBP1-KO mice and 
this percentage increased to 100% when the suspension lasted for 30 seconds 
(averaged clasping index of ~1.5±2.5). In striking contrast, none of the WT mice 
exhibited hindlimb-clasping in any of these conditions (average clasping index 
~0.5±0.1 Figure 2C, middle). Fourth, on rotarod testing, we did not detect significant 
differences between RIMBP1-KO and WT in their initial coordination nor in their 
learning rate (Supp. Figure 2C). 
As human and mouse brains display high RIMBP1 and low RIMBP2 expression in the 
striatum and the cerebellum, we hypothesized that selective lack of RIMBP1 but not of 
RIMBP2 would lead to motor abnormalities. Consistent with the expectation, and in 
striking contrast to RIMBP1-KO, RIMBP2-KO neither affected the overall locomotor 
activity or beam walk performance, nor caused limb-clasping behavior (Suppl. Figure 
3C-G). Thus, deletion of RIMBP1 but not RIMBP2 leads to motor abnormalities in 
mice.  
 
Abnormal movements and postures in RIMBP1-KO mice upon acetylcholine 
muscarinic receptor stimulation 
While RIMBP1-KO mice displayed several baseline motor abnormalities, we did not 
observe any spontaneous abnormal movements or postures, the clinical hallmark of 
dystonia. Therefore, we challenged RIMBP1-KO mice with the non-selective 
muscarinic receptor agonist oxotremorine, which has been recently shown to promote 
overt dystonia-like abnormal movements and postures in another genetic mouse 
model of dystonia (26). RIMBP1-WT and KO mice were injected with low doses of 
oxotremorine (0.01 mg/kg intraperitoneally [i.p.]), and then the appearance of abnormal 
movements and postures was assessed for up to 1-hour post injection (Figure 2D).  
RIMBP1-WT mice displayed mildly reduced spontaneous locomotion and rare events 
of head and body tremors or hindlimb extension during the first 30 minutes post 
injection only. In striking contrast, littermates RIMBP1-KO mice showed prominent and 
prolonged abnormalities in postures and movements that lasted for at least 1-hour post 
oxotremorine injections (Figure 2D, Bottom, left; supplemental video 5). These 
included a dramatic and sustained reduction in spontaneous locomotion, prolonged 
periods of immobility with hunched trunk postures associated with flexion of hindlimbs 
and extension of forelimbs, slow and uncoordinated gait with extended body and 
abnormal hindlimb postures, and frequent excessive jerking of the head and body 
twitching, prolonged motionless standing on hindlimbs with uncoordinated movements 
of the forelimbs and occasional raising of a single paw (Suppl. Video 6). A quantitative 
analysis, using an established scale for motor abnormalities in mice (26), estimated 
that oxotremorine increased motor dysfunction in RIMBP1-KO by about 300% 
compared to WT littermates (Figure 2D, Bottom, right), indicating a severe 
susceptibility to muscarinic cholinergic stimulation caused by RIMBP1 deletion.  
 
Cerebellar morphology and protein composition in mice lacking RIMBP1 
Given the presence of progressive cerebellar atrophy in subjects with homozygous 
RIMBP1 truncation and the high expression levels of RIMBP1 in cerebellar Purkinje 
cells, we asked whether RIMBP1 deletion is causally linked to morphological or 
biochemical abnormalities in the mouse cerebellum. Gross visual inspection of 
cerebelli from RIMBP1-WT and KO mice did not show obvious size differences (Figure 
3A, left) and quantitative analyses did not detect a significant difference in the 
cerebellar volume (Figure 3A, left) or the total number of Purkinje cells (Figure 3A, 
right). Furthermore, immunoblotting analysis of cerebellar lysates did not show 
significant changes in the levels of general neuronal markers between RIMBP1-WT 
and KO mice (Suppl. Figure 3). 
 
We found, however, that RIMBP1-KO led to significant morphological abnormalities in 
the dendritic arbors of Purkinje cells (Figure 3B). Quantification of the integrity of 
Purkinje cell, assessed by measuring the total area covered by Calbindin 
immunolabeling in parasagittal cerebellar sections, revealed a ~30% loss of coverage 
in the more distal portion of Purkinje cell dendritic arbors (Figure 3, right). Furthermore, 
the overall Calbindin intensity was significantly decreased throughout the cerebellum 
(31.6% reduction in the distal domain; 38.4% in the proximal domain, Figure 3B, right). 
This result was confirmed by the immunoblotting from cerebellar lysates, which 
showed a ~20% reduction of the Calbindin signal in RIMBP1-KO mice (Figure 3D).  
We also found that RIMBP1 deletion led to changes in the number of excitatory but not 
inhibitory synapses onto Purkinje cells. Purkinje cells receive two major excitatory 
inputs, parallel fibers and climbing fibers, which can be readily identified by expression 
of vesicular glutamate transporters vGluT1 or vGluT2, respectively. RIMBP1 deletion 
reduced both proximal and distal dendritic vGluT1 staining intensity by ~20% 
compared to WT controls (Figure 3C), whereas vGlut2-containing clusters were 
reduced by around ~30% in the distal and by ~15% in the proximal dendritic arbors 
(Figure 3D, E). Again, these results were confirmed by measurements of synapsin 
levels by immunoblotting from cerebellar lysates, which showed a ~20% reduction in 
RIMBP1-KO mice (Figure 3F). Immunoblotting analysis showed that neither the level 
of several active zone proteins (including RIM1 and RIMBP2) (Figure 3D, Suppl. Figure 
4 and Suppl. Table 3) nor the levels of the SNAREs and associated proteins were 
significantly different in WT and KO cerebelli. Likewise, the levels of VGCCs and BK-
channels that interact with RIMBPs, as well as the levels of several postsynaptic 
proteins found in excitatory and inhibitory synapses, were not altered (Suppl. Figure 4 
and 5).  
Importantly, histological analysis of the cerebellum of 2-month-old RIMBP1-KO mice 
showed normal Purkinje cell dendritic trees and calbindin staining (Suppl. Figure 6A-
C), consistent with the idea that in mice, like in humans, cerebellar morphological 
abnormalities due to RIMBP1 mutations are progressive in nature.  Finally, we also 
analyzed the structural integrity of the motor cortex and the striatum, two brain areas 
that play essential roles in dystonia pathogenesis. We found that neither the number 
of layer V pyramidal neurons in the motor cortex, nor the number of medium spiny 
neurons, cholinergic interneurons, or vGuT1 puncta signals in the striatum are 
changed in 6-month-old RIMBP1-KO mice (Suppl. Figure 6D, E). Together, these 
results indicate that constitutive deletion of RIMBP1 humans and mice impacts 
cerebellar but not striatal or cortical structural integrity.  
 
 
Impact of the pathogenic RIMBP1 p.Gly1808Ser substitution on synaptic 
transmission 
Subjects from family A and B described above carry TSPOAP1 truncating variants that 
essentially lead to the loss of all RIMBP1 functional domains. Therefore, these variants 
are expected to cause synaptic dysfunctions reminiscent of those observed in RIMBPs 
KO neurons, including reduced priming, uncoupling of VGCCs from the active zone, 
and reduced synaptic transmission fidelity (18, 19, 27, 28).  
Subjects from family C, in contrast, carry a missense variant (p.Gly1808Ser) that 
changes a single amino acid in the last SH3 domain of RIMBP1. Patients carrying this 
variant displayed a different dystonic phenotype, suggesting that the pathogenic 
mechanism triggered by this variant may be different from that of the truncating 
RIMBP1 variants. To address this, we used autaptic neuronal cultures (29), which 
allow for precise assessment of synaptic parameters (30) (Figure 4A). Because of the 
known functional redundancy between RIMBPs and RIMs,(19) we performed all 
experiments in neuronal cultures prepared from RIMBP1,2/RIM1,2 quadruple 
conditional KO mice (qKO).(19) These cultures were infected with Cre-recombinase to 
delete all RIMBPs and RIMs, then rescued with either the RIMBP control (RIMBP-WT) 
or RIMBP mutant (RIMBP-MUT) (Figure 4B), and analyzed via patch-clamp or Ca2+ 
imaging (Figure 4C, D).  
 
Deletion of all RIMBPs and RIMs completely blocked spike-triggered glutamate release 
from cultured neurons, as previously described (19) (Figure 4C, D). Surprisingly, 
neurons rescued with RIMBP-MUT showed, on average, nearly 100% larger excitatory 
postsynaptic current (EPSC) amplitude than RIMBP-WT, indicating that RIMBP1-
p.Gly1808Ser variant does not compromise the function of RIMBP1 but rather causes 
abnormally increased synaptic transmission. As the pathogenic variant is located in 
the last SH3 domain of RIMBP1, which binds to VGCCs at the active zone and clusters 
them in close proximity of Ca2+sensors (17) (Figure 1D), we hypothesized that 
p.Gly1808Ser may affect release by regulating the interaction with VGCCs, which in 
turn would impact total Ca2+ entry during action potential firing. Thus, we directly 
measured intra-terminal Ca2+ levels using synaptically-localized SynGCamp6F in qKO 
autaptic cultures rescued with either RIMBP-WT or MUT (Figure 4E, J). Neurons 
transduced with the RIMBP-WT rescue construct showed moderate presynaptic Ca2+ 
elevations in response to increasing numbers of action potentials (Figure 4F, G). In 
striking contrast, neurons rescued with the pathogenic RIMBP-MUT variant displayed 
more than 100% larger Ca2+ transients (Figure 4G).  
 
Finally, we studied whether p.Gly1808Ser affects the interaction of RIMBPs with 
VGCCs. We co-transfected HEK293T cells with a plasmid carrying an HA-tagged 
cytosolic C-terminal portion of the a1 subunits of P/Q (Cav2.1), known to mediate the 
interaction with RIMPBs, and a plasmid containing c-myc tagged RIMBP-WT or 
RIMBP-MUT (Figure 4H). Co-immunoprecipitation experiments revealed that RIMBP-
MUT precipitated more than 3-fold higher amounts of Cav2.1 compared to RIMBP-WT 
(Figure 4I, J, p0.03). Altogether, these experiments indicate that p.Gly1808Ser 
causes abnormally increased neurotransmitter release via a mechanism that involves 
enhanced spike-triggered presynaptic Ca2+ entry, likely by recruiting a higher number 
of VGCCs at the release sites. 
Discussion  
We report here the identification of three pathogenic homozygous variants in 
TSPOAP1, the gene encoding the active zone protein RIMBP1, as a genetic cause of 
autosomal recessive dystonia. Two of these variants (p.Ala180Profs*8 and p.Gln817*) 
result in complete loss of RIMBP1 function either through early truncations and loss of 
all functional domains or through nonsense-mediated decay. The third variant 
(p.Gly1808Ser) is a missense variant located in the last SH3 domain of RIMBP1 and 
leads to abnormally increased synaptic transmission by likely recruiting more VGCCs 
to the active zone. 
 
Clinically, the four subjects carrying homozygous truncating variants displayed a 
severe and progressive form of generalized dystonia featuring prominent cranio-
cervical involvement with onset in early teenage years. Strikingly, in these patients 
dystonia was also associated with pauci-symptomatic progressive cerebellar atrophy, 
a presentation that to date has been described in only a small number of families (31). 
On the other hand, the three subjects carrying the missense variant p.Gly1808Ser 
showed a milder phenotype featuring later onset focal dystonia, without clear evidence 
of significant cerebellar structural defects. 
 
Like in humans, complete removal of RIMBP1 in mice resulted in several motor 
abnormalities commonly observed across different genetic mouse models of dystonia 
(32). These included dramatically abnormal movements and postures in response to 
subthreshold injections of the muscarinic agonist oxotremorine, known to unmask the 
appearance of dystonia-like movements in other genetic models of dystonia (26). Loss 
of RIMBP1 in mice also resulted in structural abnormalities in the cerebellum, including 
shortening of the dendritic tree of Purkinje cells, reduced excitatory synaptic puncta, 
and abnormal cerebellar expression of synaptic markers. Importantly, we found that 
such histological abnormalities were not present in younger (2-month-old) RIMBP1-
KO mice, indicating that the loss of RIMBP1 function leads to progressive structural 
abnormalities in the cerebellum, more remarkably in cerebellar Purkinje cells. The lack 
of clinical signs of cerebellar dysfunction despite the presence of prominent cerebellar 
atrophy in subjects with homozygous TSPOAP1/RIMBP1 truncating variants is 
puzzling. We speculate that, given its progressive nature, the degree of cerebellar 
dysfunction may still be too mild to cause prominent signs of cerebellar dysfunction in 
patients that lack RIMBP1, but yet severe enough to cause subtle synaptic 
transmission abnormalities in cerebellar circuits and in other brain regions, like the 
striatum or cerebral cortex, resulting in the production of dystonic movements.  
 
Our results indicate that RIMBP1, but not RIMBP2, is a key molecular link between 
synaptic dysfunction and dystonia. This is likely because in mice and humans RIMBP1 
is heavily expressed in cerebellar Purkinje cells, where the homologous and 
functionally redundant RIMBP2 is virtually not expressed, thus preventing functional 
compensation and making Purkinje cells particularly susceptible to the effect of genetic 
variants affecting RIMBP1 function. The association of cerebellar structural 
abnormalities and dystonia observed in both humans and mice lacking RIMBP1 further 
supports the increasingly recognized role of cerebellar dysfunction in dystonia 
pathogenesis (7). Recent work in mice showed that abnormal and irregular burst firing 
of Purkinje cells, as well as in neurons in the deep cerebellar nuclei, can be observed 
in several murine models of dystonia (33-37). Furthermore, impaired cerebellar output 
may directly cause dystonia by altering basal ganglia activity and plasticity of cortico-
striatal pathways (38). In this context, given the essential role of RIMBPs in regulating 
precise and reliable synaptic release (18), we speculate that RIMBP1 deletion may 
cause irregular synaptic transmission of Purkinje cells resulting in aberrant plasticity at 
cortico-striatal synapse. This effect is likely further precipitated by oxotremorine as 
over-activation of cholinergic M1 receptors on striatal neurons has been shown to have 
a strong effect on disrupting cortico-striatal synaptic plasticity (39).  
 
It is worth emphasizing that our work does not establish a causal link between the 
observed cerebellar structural abnormalities and dystonia pathogenesis in patients and 
mice with complete RIMBP1 loss-of-function. Indeed, RIMBP1 is also highly expressed 
in the motor cortex and in the striatum, two brain structures with an established role in 
dystonia pathophysiology. Our initial histological analysis of these two regions did not 
identify major differences in cell numbers or morphology between RIMBP1-WT and 
KO mice. However, a detailed electrophysiological characterization of cerebellar and 
cortico-striatal synapses will be necessary to further understand the functional 
neuroanatomy of this condition.  Along these lines, another compelling hypothesis is 
that RIMBP1 deletion may affect the activity of olivocerebellar excitatory synapses, the 
disruption of which has been recently shown to be able to cause dystonic movements 
in mice (40). Intriguingly, we observed in the cerebelli of RIMBP1-KO mice a reduced 
number of vGLUT2 puncta, a marker of the cerebellar climbing fibers originating from 
the inferior olives, hence suggesting a possible critical role of this structure. Overall, 
circuit-specific deletions of RIMBP1, combined with behavioral analysis, will shed 
crucial insight into the contribution of subtle synaptic abnormalities in these brain 
structures to the pathogenesis RIMBP1-related dystonia. 
 
RIMBPs are enriched at the interface between the active zone cytomatrix and the 
presynaptic membrane where they directly interact with RIMs and P- and Q-type 
VGCCs via their SH3 domains. Via these interactions, RIMBPs promote accumulation 
of VGCCs (i.e. Cav2.1 and Cav2.2) at the release sites, and thereby regulate the 
dynamics of transmitter release in response to presynaptic action potentials. 
Therefore, mechanistically, RIMBP1 variants can influence synaptic function by 
altering the clustering of release-relevant presynaptic VGCCs. Loss-of-function 
variants are expected to reduce the density of active zone VGCCs, as observed in 
central synapses of mice lacking RIMBPs (18, 19, 28, 41). Conversely, the missense 
variant found in family C (p.Gly1808Ser) increased the extent of transmitter in 
response to action potentials. We also observed that this variant increased presynaptic 
Ca2+ elevation per action potential and enhanced spike-triggered intraterminal Ca2+, 
likely due to an increased number of VGCCs per active zone. Together, this indicates 
that both decreased or increased density of VGCCs at the active zone is key in 
dystonia pathogenesis. 
 
RIMBPs can also interact with presynaptic Ca2+ activated potassium channels (K-Ca2+ 
channels), in particular BK channels, via their central FN3-type domains and regulate 
their clustering at the release sites (42). Although the exact physiological significance 
of this interaction remains to be determined, it is likely that active zone BK channels 
limit the extent of membrane depolarization and transmitter release during sustained 
trains of presynaptic action potentials. Therefore, RIMBP1 variants may also alter the 
density of BK-channels. While our results indicate that the total amount of BK alpha 
subunit was not altered in RIMBP1-KO mice, it is not known if the nano-scale 
organization of BK channels might be impaired both in Purkinje cells as well as in other 
brain regions involved in dystonia pathogenesis. At the cellular level, K-Ca2+channel 
dysfunction leads to uncoordinated firing patterns in Purkinje cells, which is expected 
to alter the fidelity and reliability of information transfer to downstream targets in the 
deep cerebellar nuclei (43). This phenotype is identical to that observed upon genetic 
removal of RIMBPs from other central synapses (41). 
 
Importantly, evidence from human genetic studies supports the role of perturbed 
presynaptic neurotransmitter release in the pathogenesis of hyperkinetic movement 
disorders. Pathogenic dominant variants in the RIMBP1 binding partners CACNA1A 
and KCNMA1, encoding Cav2.1 and BK-channels respectively, have been linked to a 
variety of human movement disorders, including episodic ataxia (44) and paroxysmal 
dyskinesias (45, 46). Moreover, recessive variants in CACNA1A, CACNA1B and 
KCNMA1 cause progressive epileptic encephalopathy variably associated with 
cerebellar atrophy (47, 48) or dyskinesias (49). Furthermore, the protein product of 
PNKD, another gene linked to a paroxysmal dyskinetic movement disorder, has been 
recently shown to localize at synapses where it interacts with RIM1 and RIM2 
modulating neurotransmitter release (50). Finally, a gain-of-function missense variant 
in the presynaptic protein MUNC13A, causally linked to a complex dyskinetic 
movement disorder, was recently shown to cause pathologically enhanced 
neurotransmitter release (51), a synaptic phenotype similar to what we observed for 
the RIMBP1 variant p.Gly1808Ser.  
In conclusion, our results show that RIMBP1 dysfunction causes dystonia in humans 
and abnormal movements and postures in mice. To date, TSPOAP1/RIMBP1 
haploinsufficiency had only been genetically linked to increased risk of autism (52). 
Our results establish a causal link between dysfunction of the active zone machinery 
and dystonia in subjects with bi-allelic TSPOAP1/RIMBP1 genetic defects, which 
suggests a potential broader role for presynaptic dysfunction in dystonia pathogenesis. 
As RIMBP1 dysfunction leads to unreliable synaptic transmission, we hypothesize that 
restoring the precision of synaptic release pharmacologically may represent a 
promising therapeutic angle to treat dystonia and other hyperkinetic movement 
disorders. The RIMBP1-KO mouse model we developed could be instrumental not only 
to test this hypothesis but also to disentangle the circuit abnormalities underlying the 
pathogenesis of RIMBP1-related dystonia and to further investigate the complex 





Gene mapping.  
DNA was extracted from peripheral lymphocytes following standard protocols. A genome-wide 
analysis genotyping scan was performed in all six members of family A and in the proband of 
family B using the HumanCytoSNP-12 DNA Analysis BeadChip Kit (Illumina, San Diego), 
according to manufacturer’s instruction. Homozygosity mapping was performed using PLINK 
v.1.079 (53). In family C, homozygosity mapping was performed using Whole-exome 
sequencing data analyzed with the H3M2 software (54).  
Whole-exome sequencing.  
Whole-exome sequencing (WES) was performed in all three affected children and both parents 
for family A, in the proband only for family B and in the proband and her unaffected sibling for 
family C. WES and bioinformatic analysis were performed as previously described (55-57). 
Given the reported history of parental consanguinity in family A and the result of homozygosity 
mapping suggesting cryptic parental relatedness in family B and C, the analysis focused on 
homozygous coding and essential splice-site variants. Variants were not considered if they 
had a read depth < 5 and a minor allele frequency (MAF) > 0.005 in Exome Aggregation 
Consortium, Complete Genomics 69, 1000 Genomes project, and Exome Variant Server, as 
well as in in-house databases containing WES data from healthy controls or subjects with 
unrelated disorders. The summary of WES quality metrics for the families included in this study 
and full list of genetic variants surviving the initial filtering strategy are listed in supplemental 




We used the following mouse lines: RIMBP1-KO, RIMBP2-KO, and quadruple 
RIM1,2/RIMBP1,2-KO. Mice were generated and maintained as described previously (18, 19).  
  
Measurements of motor performance.  
All behavioral tests were performed in six-month-old mutant and control littermate male mice 
between 1 to 7 PM. 1. Open field locomotion. Mice were video-tracked in an open field arena 
for 60 minutes. Distance traveled, speed, and overall activity was analyzed using Viewer 
software. 2. Limb-clasping.  Mice were suspended by their tails for 10, 20 or 30 seconds and 
the percentage of animals displaying clasping behavior at each time point was measured. To 
quantify limb-clasping, we used the following “clasping index”: ‘0’= no clasping, ‘1’ = single limb 
clasping, and ‘2’ =clasping in two or more limbs. In all experiments, mice were videotaped and 
analysis of video-recordings was performed offline in a blind-manner. 3. Beam walking test. 
Mice were trained to cross a suspended bean over 3 consecutive day and on the fourth day, 
they were video-taped and the time that took for them to cross the beam (10-90% of total 
distance) as well as the total number of ‘slips’ during the crossing, was quantified. 
4.Accelerating rotarod. We used a five-station rotarod treadmill (ENV-575M, Med Associates) 
equipped with an 8 to 80 rpm rate of acceleration over 300 s. Time and speed to fall off was 
quantified automatically (Med Associates). 5. Motor behavior after systemic injections of 
oxotremorine. Littermates wild type and RIMBP1-KO male mice were habituated in a clear 
plastic cage for 10 minutes and then treated with an intra-peritoneal injection of 0.01mg/kg of 
oxotremorine methiodide (Sigma-Aldrich) dissolved in normal saline solution (NaCl 0.9). Mice 
were videotaped for 60 minutes and motor behavior assessed every 10 minutes using a 
previously proposed scale for quantification of abnormal movements and postures (26). Two 
observers blinded to the genotype analyzed the experiment and rated the motor behavior of 
the mice. 
  
Morphological measurements and synapse density.  
All morphological measurements were performed in six-month-old mice, except for those 
shown in Suppl. Figure 6A-C, which were done in 2-month-old mice. To obtain a quantitative 
estimation of cerebellar size, we cut (50 mm) transversally PFA-fixed cerebelli, stained them 
with DAPI, imaged them under epifluorescence microscopy, and reconstructed them in 3D 
them using ImageJ. To assess Purkinje cell number, 40 um parasagittal sections from either 
RIMBP1 WT or RIMBP1-KO mice were immunostained with calbindin antibodies, imaged 
using confocal microscopy and analyzed with NIS-Elements AR software comparing the 
density of Purkinje cells by counting their somas. To measure excitatory synapse density, the 
cerebellum of 6 RIMBP1 WT and 6 RIMBP1 KO mice was cut parasagittal (30 um), and stained 
with antibodies against Calbindin (1:4000, mouse, Sigma) to label Purkinje cell dendritic 
profiles, and either vGluT2 (1:500, guinea pig, Millipore) or vGluT1 (1:1000, guinea pig, 
Millipore) antibodies to label climbing and parallel fiber input, respectively. To measure 
inhibitory synapse density onto Purkinje cells, 4 RIMBP1 WT and 4 RIMBP1 KO cerebelli were 
cut parasagittal (30 um) and stained with antibodies anti-GAD65 (1:1000, mouse, DSHB) and 
anti-calbindin (1:1000, rabbit, Millipore). To measure morphological parameters in the striatum 
and motor cortex, the forebrain of RIMBP1 WT and RIMBP1 KO mice was cut transversally 
(30 um), and stained with antibodies against DARPP-32 (1:4000, Rabbit, Cell Signaling), ChAT 
(1:1000, Mouse, Sigma), NeuN (1:1000, Mouse, Merck Millipore), and vGluT1 (1:1000, Rabbit, 
Custom-made). Synaptic puncta were imaged using a Nikon confocal microscope (A1RSi+, 
Confocal Microscope, Nikon) controlled by the NIS-Elements AR software (Nikon). All the 
acquisition parameters were kept constant between wild-type and mutant conditions.  
  
Neuronal cultures, electrophysiology, and calcium imaging.  
Autaptic cultures from RIM1,2/RIMBP1,2 KO (qKO) mice were prepared at P1 (19, 30). Briefly, 
neurons were plated on a sparse layer of glial micro-islands under growth-permissive substrate 
to obtain single neuron microislands. 24-36 h after plating, cultures were infected with either 
Cre-expressing or a recombination-deficient delta-cre-expressing vector as a control. For 
rescue experiments, neurons were additionally infected (24-36 hours post-plating) with either 
RIMBP-WT or with RIMBP-MUT constructs carrying the pathogenic p.G1808S variant. All 
autaptic cultures were grown for at least 2 weeks before recordings. Patch-clamp 
electrophysiology was performed at DIV 14-18 using electrode filled with an intracellular 
solution containing (in mM): 136 KCl, 17.8 HEPES, 1 EGTA, 4.6 MgCl2, 4 Na2ATP, 0.3 
Na2GTP, and 12 creatine phosphate, and 50 U/ml phosphocreatine kinase (∼300 mOsm; pH 
7.4). The extracellular solution contained (in mM): 140 NaCl, 2.4 KCl, 10 HEPES, 2 CaCl2, 4 
MgCl2, and 10 glucose (pH adjusted to 7.3 with NaOH, ∼300 mOsm). Single action potentials 
were evoked via a 2 ms depolarization pulse (from -80 to 0 mV) in voltage-clamp while 
simultaneously recording evoked currents at -80 mV holding potentials (30). For presynaptic 
Ca2+ imaging, autaptic cultures were additionally infected at DIV1 with a lentivirus expressing 
SynGCamp6. To evoke action potentials, neurons were patch-clamped as indicated above 
and then spikes were triggered by direct current injection in current-clamp. Images in Ca2+ 
imaging experiments were acquired using 490-nm LED system (pE2; CoolLED) at a 20 Hz 
sampling rate with a 50 ms exposure time. 
 
Measurement of protein levels and co-immunoprecipitation.  
Protein levels were quantified in 6-month old mice via western blot. Briefly, cerebellar tissue 
was isolated manually, mechanically homogenized, solubilized in 2X Laemmli buffer, run in 4-
20% Tris/Glycine gels, transferred onto nitrocellulose membrane, and immune-labeled with an 
array of specific antibodies again multiple synaptic and cerebellar markers (see full list in 
attached SOM). Membranes were analyzed with an Odyssey Infrared Imager. For co-
immunoprecipitations experiments, 5 × 106 HEK293T cells were plated in 10-cm dishes and 
transfected with plasmids containing cDNA of mouse HA-tagged CaV2.1 (cytosolic C-terminal 
domain) and either rat myc-tagged RIMBP-WT or RIMBP-MUT (p.Gly1808Ser). The variant 
was introduced using Q5® Site-Directed Mutagenesis Kit (New England Biolabs). Cells were 
transfected with 6 μg of each plasmid using Lipofectamine 2000 (Invitrogen), harvested 24 
hours after transfection. Cells were lysed on ice for 60 min lysed in EBC lysis buffer (Boston 
BioPRoducts) containing cOmplete™, Mini, EDTA-free Protease Inhibitor Cocktail (Roche, 
11836170001) and subsequently centrifuged at 20,000 g for 10 min to remove cellular debris. 
Protein lysates were rotated overnight at 4 °C with anti-myc antibody (Cell Signaling; 9B11). 
25 µl of Dynabeads™ Protein G (Thermo Fisher Scientific) were then added to cell lysates and 
rotated at room temperature for 30 min. The samples were then washed 5X for 5 min at room 
temperature with lysis buffer. Dynabeads were finally resuspended in 2X Laemmli buffer after 
the final wash and analyzed by standard SDS/PAGE and immunoblotting.  
 
Statistics.  
Data in figures 2, 3, and 4 are mean ± SEM. Statistical significance was assessed by one-way 
ANOVA (Figure 2A, 2D left, and Figure 4D, G) with post hoc analysis (Turkey’s) (Figure 4D, 
G), Student’s two-tailed t-test (Figure 2A bar graphs, B, C, and D, right; Figure 3; Figure 4J).  
∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001; n.s., non-significant. 
 
Study Approval.  
The genetic studies were approved by the local ethics committees (Family A - University 
College London Hospitals, London, UK; Family B - University of Tartu, Tartu, Estonia; Family 
C - Istanbul University, Istanbul, Turkey). Written informed consent for sample collection and 
subsequent analysis was obtained from all individuals or their guardians prior to inclusion in 
the study. All experiments involving mice were performed in accordance with Stanford and 
Federal Guidelines and were approved by the Stanford Institutional Animal Care and Use 
Committee and the animal and the animal ethics guidelines of the University of Heidelberg, 
Germany, under license T-52/18, and according to the regulations of Berlin authorities and 
animal welfare committee of the Charité–Universitätsmedizin Berlin, Germany under license 
no. 0220/09.  
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Figure 1. Pedigrees, genetic findings, and radiological features of subjects with pathogenic 
TSPOAP1/RIMBP1 variants. A. Top. Pedigrees and variant status of affected (closed symbols) and 
healthy (open symbols) members of the three families with bi-allelic TSPOAP1 pathogenic variants. 
Bottom. Sanger sequencing validation of the variants and schematic representation of the variant effect 
on protein coding sequence. The following abbreviations are used: WT for wild-type alleles and M for 
mutant alleles. B. Brain MRI sagittal images T1-weighted images of subjects A-II.1 (age 28), A-II.2 (age 
23), A-II.4 (age 13) and B-II.1 (age 17), demonstrating cerebellar atrophy with a predominance of the 
vermis in all four subjects carrying homozygous loss-of-function variants. C. Cartoon illustrating the 
molecular interactions of RIM-binding proteins (RIMBPs) at the presynaptic active zone. RIMBPs bind 
with the first SH3 domain to Bassoon, with the FN3 domains to calcium-activated potassium channels 
(BK) and with the second and third SH3 domain to voltage-gated calcium-channels (Ca2+) and RIM 
proteins. D. Schematic representation of RIMBP1 structure including protein domains and localization 
of the identified variants. The amino acid residue p.Gly1808 is located in the C-terminal SH3 domain 
and shows complete evolutionary conservation across all species and in the human protein homolog 
RIMBP2. Asterisks indicate invariant residues (full conservation), whereas colons and periods represent 

















Figure 2. Motor abnormalities in RIMBP1-KO mice. A. Open-field locomotor activity.  Left. Locomotor 
activity as a function of time (bin width: 5 mins). Middle. Total activity in RIMBP1-WT and RIMBP1-KO 
mice. Right. Comparison of relative activity in the periphery (P, left) and the center (C, right) of the open 
field arena in control and mutant mice. B. Beam-walk test. Left. Cumulative distribution (left) and 
summary graphs (right) of total time to cross the beam in RIMBP1 WT and RIMBP1-KO mice. Right. 
Cumulative distribution (left) and summary graphs (right) of total number of slips in RIMBP1 WT and 
RIMBP1 KO mice. C. Limb clasping test. Left. Representative pictures of a RIMBP1 WT (left) and a 
RIMBP1 KO (right) during the tail suspension test used to measure limb clasping. Arrows highlight limb 
clasping in the RIMBP1 KO mouse. Left. Percentage of RIMBP1-WT and RIMBP1-KO mice displaying 
limb clasping in tail suspension test lasting 10, 20, or 30 secs. Right. Clasping index in control and 
mutant mice tail-suspended for 10, 20, or 30 secs. D. Abnormal movements and postures triggered by 
systemic oxotremorine. Top. Examples of abnormal postures (arrows) found in RIMBP1-KO after 
oxotremorine treatment (0.01mg/Kg). Bottom, Left. Time course of abnormal motor scores after 
oxotremorine treatment (0.01mg/Kg). Motor scores were assessed in 2 minutes bins. Abnormal motor 
score scale: 0=Normal motor behavior; abnormal motor scores scale: 1= No impairment but slightly 
slowed movements; 2= Mild impairment: occasional abnormal postures and movements; ambulation 
with slow walk; 3=Moderate impairment: frequent abnormal postures and movements with limited 
ambulation; 4=Severe impairment: sustained abnormal postures without any ambulation or upright 
position. Bottom, right. Summed abnormal motor scores recorded for 60 minutes after drug injection.  
Data are meanSEM. Number of experiments: A, right: 19 WT, 16 KO; B: 10 WT, 10 KO; C: 10 WT, 10 
KO; D: 9 WT, 10 KO. Statistical analysis was assessed by one-way ANOVA (A left, D left), Student’s t-
















Figure 3. Cerebellar abnormalities in RIMBP1-KO mice. A. Gross anatomy of the cerebellum. Left. 
Dorsal view of RIMBP1-WT and RIMBP1-KO brains. Middle. Confocal image of a parasagittal section 
stained with DAPI and antibodies anti-calbindin (green). Right. Summary plot of cerebellar volume (left), 
and of Purkinje cell (PC) number (right). Scale bars: 0.8 cm and 20 m. B. Structure of PC dendrites in 
RIMBP1 control and mutant mice. Left. Low-magnification images of parasagittal sections stained with 
anti-Calbindin antibodies. Middle. High-magnification images (single optical sections) of the areas 
indicated with the white boxes on the left displaying outer (0-40%) and inner (40-80%) PC dendritic 
domains. Right. Top, summary graphs of calbindin coverage (area) in different PC dendritic domains. 
Bottom, summary graphs of calbindin intensity signal in the same PC dendritic domains. Scale bars: 1 
mm and 40 m. C. Organization of parallel fiber synapses. Left, representative confocal images of 
cerebellar sections from a RIMBP1-WT mouse. Middle, representative images from a littermate 
RIMBP1-KO mouse. Sections were stained for calbindin (green, to label PCs), for vGluT1 (red, to 
visualize parallel fibers), and for DAPI (blue, cell nuclei). Right, summary graphs of vGluT1 intensity for 
the outermost and innermost PC dendritic domains in RIMBP1 WT and littermates KO mice. Scale bar: 
40 m. D, E. Same as in C but for climbing fiber synapses stained with antibodies anti-vGluT2. In this 
case, the density (D, right) and the size (E) of vGluT2-containing puncta, was compared. Scale bar: 
40m. F. Levels of key proteins in cerebellar lysates. Left, representative blots. Right. Summary plots 
of band intensity values normalized to Tuj1.  
Data are meanSEM. Statistical analysis was assessed by Student’s t-test. ∗p < 0.05 and ∗∗∗p < 0.001; 
n.s., non-significant. Number of experiments (mice/sections): A. Left: 5 WT, 6 KO. Right: 6/62WT, 6/47 
KO. B. Intensity: 6/59 WT, 6/64 KO. Area: 6/57 WT, 6/60 KO. C. vGluT1:6/59 WT, 6/56 KO. D, E. 
































Figure 4.  Impact of RIMBP1-p.Gly1808Ser variant on synaptic transmission. A, B.   Hippocampal 
autapses for assessing the role of p.Gly1808Ser on synaptic transmission in vitro. A. Synaptic 
transmission in autapses was measured by whole-cell patch clamp recordings. Hippocampal autapses 
were prepared from RIMBP1,2/RIM1,2 quadruple conditional KO mice, and infected with lentiviruses 
expressing a recombinase-deficient version of Cre as control (‘Cre’), Cre-recombinase (‘Cre’), 
Cre+RIMBP-WT, and Cre+RIMBP-MUT constructs. B. RIMBP levels in the presence of lentiviruses 
expressing Cre, Cre, Cre+RIMBP-WT, and Cre+RIMBP-MUT. In this experiment, -tubulin was used 
as a loading control. C. Representative recordings of single action-potential evoked release (EPSC) in 
hippocampal autapses. D. Summary graphs of EPSC amplitudes rescued with either RIMBP-WT or with 
the pathogenic RIMBP-MUT construct. E-G. Direct measurements of spike-triggered presynaptic 
calcium entry.  E.  Fluorescent images of a representative hippocampal dendrite expressing 
SynGCaMP6f under basal conditions (0 AP), or after 1, 10, and 100 action potentials (APs). F. Time 
course of presynaptic fluorescence signals (F/F0) as a function of time following 1, 2, 5, or 10 APs G. 
Summary graph of presynaptic fluorescence signals for different AP frequencies in autaptic cultures 
infected with viruses expressing Cre+RIMBP-WT and Cre+RIMBP-MUT (scale bar 2.5 um).  H-J. 
RIMBP pathogenic missense variant impacts RIMBP-Ca2+-channel interaction. H. Experimental strategy 
for assessing the interaction of RIMBP with calcium-channel using co-immunoprecipitations (co-IPs). I. 
Cell lysates from HEK293T cells expressing CaV2.1-HA tagged and RIMBP-WT-myc tagged, or 
CaV2.1-HA tagged and RIMBP-MUT-myc tagged were subjected to immunoprecipitations with myc-
antibodies. Input fractions (left; 1% of total) and immunoprecipitates (IP) were analyzed by 
immunoblotting with the following antibodies: myc-epitope (RIMBP), HA-epitope (CaV2.1), and GAPDH 
as a negative control. J. Summary graph of three co-immunoprecipitation experiments performed as 
in I. 
Data are meanSEM. Statistical analysis was assessed by one-way ANOVA with post hoc analysis 
(Turkey’s, D, G), and Student’s t-test (J). ∗p < 0.05 and ∗∗∗p < 0.001; n.s., non-significant. Number of 
experiments (cells/cultures): C, D. Cre (32/3); Cre (24/3); RIMBP-WT (43/3), RIMBP-MUT (35/3). F, 
G. Cre+RIMBP-WT (17/3), Cre+RIMBP-MUT (16/3). J. RIMBP-WT (3), Cre+RIMBP-MUT (3). 
 
Table 1- Clinical features of subjects with homozygous pathogenic TSPOAP1 variants 
 A-II.1 A-II.2 A-II.4 B-II.1 C-II.1 C-II.3 C-II.4 
Gender Female Male Male Male Male Male Female 
Origin Indian Gujarati Indian Gujarati Indian Gujarati Estonian Turkish Turkish Turkish 
Age at last 
examination 
















Motor  development Normal Normal Normal Normal Normal Normal Normal 
Dystonia 
characteristics 
       
Age at onset of 
motor symptoms (y) 
12 12 13 11 ~60s 67 58 
Symptoms at 
presentation 
Loss of voice and 
speech difficulties 
Speech difficulties 
Rapid onset of 
speech difficulties 
Dystonic movements in 
right hand and leg 








severe dysarthria and 
dysphonia, dysphagia, 






Anarthria and severe 
oral dystonia, severe 
dysphagia, frequent 
spasms of plastysma 
muscle activated by 
attempts to speak 
(13) 
Mild dysarthria progressed 
into severe dysarthria and 
orofacial-mandibular 
dystonia, blepharospasm, 





tremor, mild right 
torticollis 
Retrocollis, right 

























by action and with 
muscle overflow, 




posturing and movements 
worsened by action, 
muscle overflow, impaired 






Mild bilateral writhing 
movements 
Onset of lower limb 
involvement (onset, 
y) 
Tiptoe walking with 
extreme knee flexion 
(17) 
Bilateral foot inward 
turning (16) 
Bilateral foot inward 
turning (16) 
Bilateral foot inward turning 
(11) 
None None None 












Focal Focal Focal 
Gait 
Able to walk only with 
support; severe 
dystonic features 
Possible only for short 
distances; dystonic 
gait 





Possible only for short 
distances, very unsteady, 
tiptoe walking, knee flexion 
and severe dystonic 
posturing, narrow-based 









since school; cognitive 




cognitive decline (not 
formally tested) 
Progression from mild 
(11y) to moderate 







Cerebellar signs None 
Square wave jerks, 
slow and hypometric 
saccades, mild 
intentional tremor and 
dysmetria in 4 limbs, 
broad base 
Square wave jerks, 












responsive to AEDs 





conic seizures with 
onset at age 4, 
resolved by age 10 
Rigidity in right limbs None None 
Bilateral Babinski 
sign 
Brain MRI Cerebellar atrophy Cerebellar atrophy Cerebellar atrophy Cerebellar atrophy NA NA 
Reported as normal  
(Images NA) 
Treatment trials 
BCF, TBZ, LD, BT (not 
effective). Currently on 
CNZ 0.5 mg BID and 
THP 2 mg OD 
LD (no benefit). 




THP, BT (not 
effective), currently on 
CNZ 
LD, CBZ (no benefit). 
Currently on LV (some 
initial benefit), TBZ (some 
benefit), BT (some benefit) 
None None 







SCA1, SCA2, SCA3, 
SCA6, SCA7, SCA12, 
SCA17, DRPLA, 
CSTB, FTXN, TOR1A 
TOR1A, GCH1, 
SGCE, ATM; normal 
chromosomal 
microarray 
TH, GCH1, HTT, ATP7B None None HTT 
Previous 
investigations 
Normal copper and 
ceruloplasmin, ferritin, 
acanthocytes, serum 
and urine amino and 
organic acid, VLCFA, 
blood smear, phytanic 
and pristanic acid 
Normal white blood 
cell enzyme analysis, 
purine metabolism, 
CSF (except marginal 
5-MTHF deficiency) 
Normal EMG and 
NCS 
Normal serum and urine 
amino and organic acids, 
MPS and sialic acid, 
purine/pyrimidines, CSF 
(except diminished level of 
5-MTHF). Normal EMG 
and NCS. Muscle biopsy 
(scattered angular atrophic 
muscle fibers referring to 
denervated fibers) 
None None 
Normal EMG and 
NCS 
AEs=antiepileptic drugs, BCF=baclofen, TBZ=tetrabenazine, LD=levodopa, BT=botulinum toxin, CNZ=clonazepam, THP=trihexyphenidyl, PHT=phenytoin 
CBZ=carbamazepine, LV=leucovorin, EMG=electromyography, NCS= nerve conduction studies. 5-MTHF=5-methyltetrahydrofolate. MPS= mucopolysaccharides 
NA=not available a NCBI transcript NM_004758. 
 
 
